{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:21:21Z","timestamp":1790112081842,"version":"4.0.1"},"reference-count":97,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Head and Neck CR UK Programme Grant","award":["A13407"],"award-info":[{"award-number":["A13407"]}]},{"name":"NIHR RM\/ICR Biomedical Research Centre"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.clon.2014.01.009","type":"journal-article","created":{"date-parts":[[2014,2,26]],"date-time":"2014-02-26T03:30:52Z","timestamp":1393385452000},"page":"257-265","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":92,"title":["Selective Targeting of the G2\/M Cell Cycle Checkpoint to Improve the Therapeutic Index of Radiotherapy"],"prefix":"10.1016","volume":"26","author":[{"given":"M.T.","family":"Dillon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.S.","family":"Good","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.J.","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7267","key":"10.1016\/j.clon.2014.01.009_bib1","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/nature08467","article-title":"The DNA-damage response in human biology and disease","volume":"461","author":"Jackson","year":"2009","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.clon.2014.01.009_bib2","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.clon.2014.01.009_bib3","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.clon.2013.06.007","article-title":"Biological consequences of radiation-induced DNA damage: relevance to radiotherapy","volume":"25","author":"Lomax","year":"2013","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"2","key":"10.1016\/j.clon.2014.01.009_bib4","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.molcel.2010.09.019","article-title":"The DNA damage response: making it safe to play with knives","volume":"40","author":"Ciccia","year":"2010","journal-title":"Mol Cell"},{"issue":"9","key":"10.1016\/j.clon.2014.01.009_bib5","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.dnarep.2009.04.012","article-title":"Taking the time to make important decisions: the checkpoint effector kinases Chk1 and Chk2 and the DNA damage response","volume":"8","author":"Stracker","year":"2009","journal-title":"DNA Repair (Amst)"},{"issue":"2","key":"10.1016\/j.clon.2014.01.009_bib6","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1158\/1078-0432.CCR-09-1029","article-title":"New insights into checkpoint kinase 1 in the DNA damage response signaling network","volume":"16","author":"Dai","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.clon.2014.01.009_bib7","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/1078-0432.CCR-10-1215","article-title":"Tumor suppressor CHK2: regulator of DNA damage response and mediator of chromosomal stability","volume":"17","author":"Stolz","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.clon.2014.01.009_bib8","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.molcel.2007.11.015","article-title":"The DNA damage response: ten years after","volume":"28","author":"Harper","year":"2007","journal-title":"Mol Cell"},{"issue":"3","key":"10.1016\/j.clon.2014.01.009_bib9","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nrc1011","article-title":"ATM and related protein kinases: safeguarding genome integrity","volume":"3","author":"Shiloh","year":"2003","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"10.1016\/j.clon.2014.01.009_bib10","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nrm2450","article-title":"ATR: an essential regulator of genome integrity","volume":"9","author":"Cimprich","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"Pt 3","key":"10.1016\/j.clon.2014.01.009_bib11","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1242\/jcs.035105","article-title":"ATR signaling at a glance","volume":"122","author":"Shiotani","year":"2009","journal-title":"J\u00a0Cell Sci"},{"issue":"3","key":"10.1016\/j.clon.2014.01.009_bib12","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.tibs.2010.09.005","article-title":"ATR: a master conductor of cellular responses to DNA replication stress","volume":"36","author":"Flynn","year":"2011","journal-title":"Trends Biochem Sci"},{"issue":"8","key":"10.1016\/j.clon.2014.01.009_bib13","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1101\/gad.1550307","article-title":"Single- and double-stranded DNA: building a trigger of ATR-mediated DNA damage response","volume":"21","author":"Zou","year":"2007","journal-title":"Genes Dev"},{"issue":"9","key":"10.1016\/j.clon.2014.01.009_bib14","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1101\/gad.1301205","article-title":"Functional uncoupling of MCM helicase and DNA polymerase activities activates the ATR-dependent checkpoint","volume":"19","author":"Byun","year":"2005","journal-title":"Genes Dev"},{"issue":"1","key":"10.1016\/j.clon.2014.01.009_bib15","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/ncb1337","article-title":"ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks","volume":"8","author":"Jazayeri","year":"2006","journal-title":"Nat Cell Biol"},{"issue":"2","key":"10.1016\/j.clon.2014.01.009_bib16","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1084\/jem.20051923","article-title":"ATM regulates ATR chromatin loading in response to DNA double-strand breaks","volume":"203","author":"Cuadrado","year":"2006","journal-title":"J\u00a0Exp Med"},{"issue":"1","key":"10.1016\/j.clon.2014.01.009_bib17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.molcel.2005.11.015","article-title":"Multiple mechanisms control chromosome integrity after replication fork uncoupling and restart at irreparable UV lesions","volume":"21","author":"Lopes","year":"2006","journal-title":"Mol Cell"},{"issue":"4","key":"10.1016\/j.clon.2014.01.009_bib18","doi-asserted-by":"crossref","first-page":"414","DOI":"10.4161\/cc.6.4.3886","article-title":"ATM and ATR, components of an integrated circuit","volume":"6","author":"Hurley","year":"2007","journal-title":"Cell Cycle"},{"issue":"1","key":"10.1016\/j.clon.2014.01.009_bib19","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/emboj\/17.1.159","article-title":"Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA-damaging agents and defects in cell cycle checkpoints","volume":"17","author":"Cliby","year":"1998","journal-title":"EMBO J"},{"issue":"7","key":"10.1016\/j.clon.2014.01.009_bib20","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/cdd.2008.47","article-title":"Death through a tragedy: mitotic catastrophe","volume":"15","author":"Vakifahmetoglu","year":"2008","journal-title":"Cell Death Differ"},{"issue":"8","key":"10.1016\/j.clon.2014.01.009_bib21","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nrc1412","article-title":"Pathways of apoptotic and non-apoptotic death in tumour cells","volume":"4","author":"Okada","year":"2004","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"10.1016\/j.clon.2014.01.009_bib22","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s13277-010-0042-8","article-title":"Radiation-induced cell death mechanisms","volume":"31","author":"Eriksson","year":"2010","journal-title":"Tumour Biol"},{"issue":"3","key":"10.1016\/j.clon.2014.01.009_bib23","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nrc1560","article-title":"The role of apoptosis in cancer development and treatment response","volume":"5","author":"Brown","year":"2005","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"10.1016\/j.clon.2014.01.009_bib24","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/35106009","article-title":"Assessing TP53 status in human tumours to evaluate clinical outcome","volume":"1","author":"Soussi","year":"2001","journal-title":"Nat Rev Cancer"},{"issue":"5393","key":"10.1016\/j.clon.2014.01.009_bib25","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.282.5393.1497","article-title":"Requirement for p53 and p21 to sustain G2 arrest after DNA damage","volume":"282","author":"Bunz","year":"1998","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.clon.2014.01.009_bib26","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/carcin\/bgl214","article-title":"p53-based cancer therapies: is defective p53 the Achilles heel of the tumor?","volume":"28","author":"Levesque","year":"2007","journal-title":"Carcinogenesis"},{"issue":"3","key":"10.1016\/j.clon.2014.01.009_bib27","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.radonc.2012.01.005","article-title":"DNA damage by X-rays and their impact on replication processes","volume":"102","author":"Parplys","year":"2012","journal-title":"Radiother Oncol"},{"issue":"12","key":"10.1016\/j.clon.2014.01.009_bib28","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.dnarep.2010.09.012","article-title":"The ATR barrier to replication-born DNA damage","volume":"9","author":"Lopez-Contreras","year":"2010","journal-title":"DNA Repair (Amst)"},{"issue":"9","key":"10.1016\/j.clon.2014.01.009_bib29","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1128\/MCB.25.9.3553-3562.2005","article-title":"Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage","volume":"25","author":"Syljuasen","year":"2005","journal-title":"Mol Cell Biol"},{"issue":"2","key":"10.1016\/j.clon.2014.01.009_bib30","doi-asserted-by":"crossref","first-page":"235","DOI":"10.4161\/cc.4.2.1466","article-title":"ATM and ATR check in on origins: a dynamic model for origin selection and activation","volume":"4","author":"Shechter","year":"2005","journal-title":"Cell Cycle"},{"issue":"18","key":"10.1016\/j.clon.2014.01.009_bib31","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1038\/sj.onc.1210049","article-title":"Human cancer cells require ATR for cell cycle progression following exposure to ionizing radiation","volume":"26","author":"Hurley","year":"2007","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.clon.2014.01.009_bib32","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nsmb.2076","article-title":"A\u00a0cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations","volume":"18","author":"Toledo","year":"2011","journal-title":"Nat Struct Mol Biol"},{"issue":"1","key":"10.1016\/j.clon.2014.01.009_bib33","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1172\/JCI58928","article-title":"Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR","volume":"122","author":"Schoppy","year":"2012","journal-title":"J\u00a0Clin Invest"},{"issue":"23","key":"10.1016\/j.clon.2014.01.009_bib34","doi-asserted-by":"crossref","first-page":"9693","DOI":"10.1158\/0008-5472.CAN-10-2286","article-title":"Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner","volume":"70","author":"Gilad","year":"2010","journal-title":"Cancer Res"},{"issue":"24","key":"10.1016\/j.clon.2014.01.009_bib35","doi-asserted-by":"crossref","first-page":"11648","DOI":"10.1158\/0008-5472.CAN-07-3100","article-title":"Different S\/M checkpoint responses of tumor and non-tumor cell lines to DNA replication inhibition","volume":"67","author":"Rodriguez-Bravo","year":"2007","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.clon.2014.01.009_bib36","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.molonc.2011.07.002","article-title":"Targeting ATR and Chk1 kinases for cancer treatment: a new model for new (and old) drugs","volume":"5","author":"Toledo","year":"2011","journal-title":"Mol Oncol"},{"issue":"10","key":"10.1016\/j.clon.2014.01.009_bib37","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/ng.441","article-title":"Tissue regenerative delays and synthetic lethality in adult mice after combined deletion of Atr and Trp53","volume":"41","author":"Ruzankina","year":"2009","journal-title":"Nat Genet"},{"issue":"4755","key":"10.1016\/j.clon.2014.01.009_bib38","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1126\/science.2422760","article-title":"Caffeine-induced uncoupling of mitosis from the completion of DNA replication in mammalian cells","volume":"232","author":"Schlegel","year":"1986","journal-title":"Science"},{"issue":"16","key":"10.1016\/j.clon.2014.01.009_bib39","doi-asserted-by":"crossref","first-page":"9092","DOI":"10.1073\/pnas.161281798","article-title":"ATR inhibition selectively sensitizes G1 checkpoint-deficient cells to lethal premature chromatin condensation","volume":"98","author":"Nghiem","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"10.1016\/j.clon.2014.01.009_bib40","first-page":"1643","article-title":"Differential sensitivity of p53(\u2013) and p53(+) cells to caffeine-induced radiosensitization and override of G2 delay","volume":"55","author":"Powell","year":"1995","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.clon.2014.01.009_bib41","first-page":"1639","article-title":"Abrogation of the G2 checkpoint results in differential radiosensitization of G1 checkpoint-deficient and G1 checkpoint-competent cells","volume":"55","author":"Russell","year":"1995","journal-title":"Cancer Res"},{"issue":"14","key":"10.1016\/j.clon.2014.01.009_bib42","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1093\/jnci\/88.14.956","article-title":"UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53","volume":"88","author":"Wang","year":"1996","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"8","key":"10.1016\/j.clon.2014.01.009_bib43","first-page":"2108","article-title":"The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1","volume":"60","author":"Busby","year":"2000","journal-title":"Cancer Res"},{"issue":"17","key":"10.1016\/j.clon.2014.01.009_bib44","first-page":"4375","article-title":"Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine","volume":"59","author":"Sarkaria","year":"1999","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.clon.2014.01.009_bib45","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1101\/gad.14.4.397","article-title":"ATR disruption leads to chromosomal fragmentation and early embryonic lethality","volume":"14","author":"Brown","year":"2000","journal-title":"Genes Dev"},{"issue":"12","key":"10.1016\/j.clon.2014.01.009_bib46","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1101\/gad.14.12.1439","article-title":"Aberrant cell cycle checkpoint function and early embryonic death in Chk1(\u2013\/\u2013) mice","volume":"14","author":"Takai","year":"2000","journal-title":"Genes Dev"},{"issue":"4","key":"10.1016\/j.clon.2014.01.009_bib47","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/ng1129","article-title":"A\u00a0splicing mutation affecting expression of ataxia-telangiectasia and Rad3-related protein (ATR) results in Seckel syndrome","volume":"33","author":"O'Driscoll","year":"2003","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.clon.2014.01.009_bib48","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1158\/1535-7163.MCT-06-0679","article-title":"Loss of ataxia telangiectasia mutated- and Rad3-related function potentiates the effects of chemotherapeutic drugs on cancer cell survival","volume":"6","author":"Wilsker","year":"2007","journal-title":"Mol Cancer Ther"},{"issue":"22","key":"10.1016\/j.clon.2014.01.009_bib49","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1038\/onc.2010.624","article-title":"ATR mediates cisplatin resistance in a p53 genotype-specific manner","volume":"30","author":"Sangster-Guity","year":"2011","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.clon.2014.01.009_bib50","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1158\/1535-7163.MCT-08-1135","article-title":"Ataxia telangiectasia and rad3-related kinase contributes to cell cycle arrest and survival after cisplatin but not oxaliplatin","volume":"8","author":"Lewis","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clon.2014.01.009_bib51","doi-asserted-by":"crossref","first-page":"e699","DOI":"10.1038\/cddis.2013.227","article-title":"Repression of ATR pathway by miR-185 enhances radiation-induced apoptosis and proliferation inhibition","volume":"4","author":"Wang","year":"2013","journal-title":"Cell Death Dis"},{"issue":"3","key":"10.1016\/j.clon.2014.01.009_bib52","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/emboj\/cdg060","article-title":"Chk1-deficient tumour cells are viable but exhibit multiple checkpoint and survival defects","volume":"22","author":"Zachos","year":"2003","journal-title":"EMBO J"},{"issue":"2","key":"10.1016\/j.clon.2014.01.009_bib53","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/bjc.2012.265","article-title":"Targeting radiation-resistant hypoxic tumour cells through ATR inhibition","volume":"107","author":"Pires","year":"2012","journal-title":"Br J Cancer"},{"issue":"37","key":"10.1016\/j.clon.2014.01.009_bib54","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1038\/onc.2012.462","article-title":"ATR controls cellular adaptation to hypoxia through positive regulation of hypoxia-inducible factor 1 (HIF-1) expression","volume":"32","author":"Fallone","year":"2013","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.clon.2014.01.009_bib55","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nchembio.573","article-title":"Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR","volume":"7","author":"Reaper","year":"2011","journal-title":"Nat Chem Biol"},{"issue":"11","key":"10.1016\/j.clon.2014.01.009_bib56","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.4161\/cbt.21093","article-title":"The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy","volume":"13","author":"Prevo","year":"2012","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.clon.2014.01.009_bib57","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1038\/cddis.2012.181","article-title":"Targeting ATR in\u00a0vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation","volume":"3","author":"Fokas","year":"2012","journal-title":"Cell Death Dis"},{"issue":"3","key":"10.1016\/j.clon.2014.01.009_bib58","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/bjc.2011.243","article-title":"Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines","volume":"105","author":"Peasland","year":"2011","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.clon.2014.01.009_bib59","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1158\/1535-7163.MCT-12-0879","article-title":"The efficacy of CHK1 inhibitors is not altered by hypoxia, but is enhanced after reoxygenation","volume":"12","author":"Hasvold","year":"2013","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"10.1016\/j.clon.2014.01.009_bib60","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1200\/JCO.2001.19.8.2319","article-title":"Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms","volume":"19","author":"Sausville","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.clon.2014.01.009_bib61","doi-asserted-by":"crossref","first-page":"4444","DOI":"10.1158\/1078-0432.CCR-04-2602","article-title":"The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California Cancer Consortium phase I pharmacokinetic and molecular correlative trial","volume":"11","author":"Lara","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.clon.2014.01.009_bib62","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/annonc\/mdj076","article-title":"Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study","volume":"17","author":"Hotte","year":"2006","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.clon.2014.01.009_bib63","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1200\/JCO.2005.03.116","article-title":"Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with fluorouracil in patients with advanced solid tumors","volume":"23","author":"Kortmansky","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.clon.2014.01.009_bib64","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.3109\/10428194.2011.589547","article-title":"Phase I trial of 7-hydroxystaurosporine and fludararbine phosphate: in\u00a0vivo evidence of 7-hydroxystaurosporine induced apoptosis in chronic lymphocytic leukemia","volume":"52","author":"Marti","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.clon.2014.01.009_bib65","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.molmed.2010.10.009","article-title":"Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics","volume":"17","author":"Ma","year":"2011","journal-title":"Trends Mol Med"},{"issue":"2","key":"10.1016\/j.clon.2014.01.009_bib66","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s10549-012-2378-9","article-title":"A\u00a0phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer","volume":"137","author":"Ma","year":"2013","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.clon.2014.01.009_bib67","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s10637-010-9562-8","article-title":"A\u00a0phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial","volume":"30","author":"Li","year":"2012","journal-title":"Invest New Drugs"},{"issue":"2","key":"10.1016\/j.clon.2014.01.009_bib68","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ygyno.2007.02.018","article-title":"UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: a study of the Princess Margaret Hospital Phase II consortium","volume":"106","author":"Welch","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"7","key":"10.1016\/j.clon.2014.01.009_bib69","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1158\/1078-0432.CCR-09-3277","article-title":"In\u00a0vitro and in\u00a0vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762","volume":"16","author":"Mitchell","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.clon.2014.01.009_bib70","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1158\/1535-7163.MCT-13-0157","article-title":"Chk1\/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53","volume":"12","author":"Gadhikar","year":"2013","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"10.1016\/j.clon.2014.01.009_bib71","doi-asserted-by":"crossref","first-page":"4972","DOI":"10.1158\/0008-5472.CAN-09-3573","article-title":"Mechanism of radiosensitization by the Chk1\/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair","volume":"70","author":"Morgan","year":"2010","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.clon.2014.01.009_bib72","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00280-013-2234-6","article-title":"Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours","volume":"72","author":"Seto","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"10.1016\/j.clon.2014.01.009_bib73","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.radonc.2013.06.035","article-title":"HPV-positive HNSCC cell lines but not primary human fibroblasts are radiosensitized by the inhibition of Chk1","volume":"108","author":"Busch","year":"2013","journal-title":"Radiother Oncol"},{"issue":"15s","key":"10.1016\/j.clon.2014.01.009_bib74","article-title":"Phase I clinical trial of gemcitabine (GEM) in combination with PF-00477736 (PF-736), a selective inhibitor of CHK1 kinase","volume":"28","author":"Brega","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"10.1016\/j.clon.2014.01.009_bib75","doi-asserted-by":"crossref","first-page":"4412","DOI":"10.1158\/1078-0432.CCR-12-3748","article-title":"Sensitization of pancreatic cancer to chemoradiation by the Chk1 inhibitor MK8776","volume":"19","author":"Engelke","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"15s","key":"10.1016\/j.clon.2014.01.009_bib76","article-title":"A\u00a0phase I dose-escalation study of SCH 900776, a selective inhibitor of checkpoint kinase 1 (CHK1), in combination with gemcitabine (Gem) in subjects with advanced solid tumors","volume":"28","author":"Daud","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"10.1016\/j.clon.2014.01.009_bib77","doi-asserted-by":"crossref","first-page":"6723","DOI":"10.1158\/1078-0432.CCR-12-2442","article-title":"Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias","volume":"18","author":"Karp","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.clon.2014.01.009_bib78","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1158\/1535-7163.MCT-11-0406","article-title":"Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites","volume":"11","author":"Montano","year":"2012","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"10.1016\/j.clon.2014.01.009_bib79","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.ijrobp.2012.08.006","article-title":"Targeted radiosensitization by the Chk1 inhibitor SAR-020106","volume":"85","author":"Borst","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.clon.2014.01.009_bib80","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/nar\/gkr697","article-title":"Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication","volume":"40","author":"Sorensen","year":"2012","journal-title":"Nucleic Acids Res"},{"issue":"17","key":"10.1016\/j.clon.2014.01.009_bib81","doi-asserted-by":"crossref","first-page":"5638","DOI":"10.1158\/1078-0432.CCR-11-0650","article-title":"MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells","volume":"17","author":"Bridges","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.clon.2014.01.009_bib82","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1158\/1078-0432.CCR-10-2580","article-title":"MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts","volume":"17","author":"Rajeshkumar","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.clon.2014.01.009_bib83","doi-asserted-by":"crossref","first-page":"514","DOI":"10.4161\/cbt.9.7.11115","article-title":"MK-1775, a small molecule Wee1 inhibitor, enhances antitumor efficacy of various DNA-damaging agents, including 5-fluorouracil","volume":"9","author":"Hirai","year":"2010","journal-title":"Cancer Biol Ther"},{"issue":"Suppl.","key":"10.1016\/j.clon.2014.01.009_bib84","article-title":"Targeting p53 mutant ovarian cancer: phase I results of the WEE1 inhibitor MK-1775 with carboplatin plus paclitaxel in patients (pts) with platinum-sensitive, p53-mutant ovarian cancer","author":"Brana","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2014.01.009_bib85","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/1471-2407-6-292","article-title":"Cell cycle regulation by the Wee1 inhibitor PD0166285, pyrido [2,3-d] pyimidine, in the B16 mouse melanoma cell line","volume":"6","author":"Hashimoto","year":"2006","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.clon.2014.01.009_bib86","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ceb.2006.02.003","article-title":"The when and wheres of CDC25 phosphatases","volume":"18","author":"Boutros","year":"2006","journal-title":"Curr Opin Cell Biol"},{"issue":"6","key":"10.1016\/j.clon.2014.01.009_bib87","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/ijc.24080","article-title":"IRC-083864, a novel bis quinone inhibitor of CDC25 phosphatases active against human cancer cells","volume":"124","author":"Brezak","year":"2009","journal-title":"Int J Cancer"},{"issue":"5","key":"10.1016\/j.clon.2014.01.009_bib88","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/bjc.2011.240","article-title":"Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers","volume":"105","author":"Harrington","year":"2011","journal-title":"Br J Cancer"},{"issue":"56","key":"10.1016\/j.clon.2014.01.009_bib89","doi-asserted-by":"crossref","first-page":"7773","DOI":"10.1038\/sj.onc.1210881","article-title":"DNA damage signalling guards against activated oncogenes and tumour progression","volume":"26","author":"Bartek","year":"2007","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.clon.2014.01.009_bib90","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1021\/cb4001537","article-title":"CH-01 is a hypoxia-activated prodrug that sensitizes cells to hypoxia\/reoxygenation through inhibition of Chk1 and Aurora A","volume":"8","author":"Cazares-Korner","year":"2013","journal-title":"ACS Chem Biol"},{"issue":"15","key":"10.1016\/j.clon.2014.01.009_bib91","first-page":"5843","article-title":"Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells","volume":"61","author":"Hirose","year":"2001","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.clon.2014.01.009_bib92","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1365-2184.2010.00685.x","article-title":"p53-dependent G(1) arrest in 1st or 2nd cell cycle may protect human cancer cells from cell death after treatment with ionizing radiation and Chk1 inhibitors","volume":"43","author":"Petersen","year":"2010","journal-title":"Cell Prolif"},{"issue":"23","key":"10.1016\/j.clon.2014.01.009_bib93","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1038\/sj.onc.1208451","article-title":"Distinct roles for p53 transactivation and repression in preventing UCN-01-mediated abrogation of DNA damage-induced arrest at S and G2 cell cycle checkpoints","volume":"24","author":"Levesque","year":"2005","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.clon.2014.01.009_bib94","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/nrc864","article-title":"Live or let die: the cell's response to p53","volume":"2","author":"Vousden","year":"2002","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"10.1016\/j.clon.2014.01.009_bib95","doi-asserted-by":"crossref","first-page":"572","DOI":"10.4161\/cc.6.5.3926","article-title":"G2 checkpoint kinase inhibitors exert their radiosensitizing effects prior to the G2\/M transition","volume":"6","author":"Sturgeon","year":"2007","journal-title":"Cell Cycle"},{"issue":"2","key":"10.1016\/j.clon.2014.01.009_bib96","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1124\/mi.11.2.11","article-title":"CHK1 inhibitors in combination chemotherapy: thinking beyond the cell cycle","volume":"11","author":"Dent","year":"2011","journal-title":"Mol Interv"},{"issue":"24","key":"10.1016\/j.clon.2014.01.009_bib97","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.4161\/cc.10.24.18661","article-title":"Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1","volume":"10","author":"Vance","year":"2011","journal-title":"Cell Cycle"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655514000673?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655514000673?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:39:40Z","timestamp":1760542780000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655514000673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":97,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0936655514000673"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2014.01.009","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selective Targeting of the G2\/M Cell Cycle Checkpoint to Improve the Therapeutic Index of Radiotherapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2014.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}